Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares traded down 8.6% on Thursday . The stock traded as low as $9.43 and last traded at $9.56. 1,284,800 shares changed hands during mid-day trading, an increase of 104% from the average session volume of 630,905 shares. The stock had previously closed at $10.46.
Several research analysts recently weighed in on the stock. BidaskClub cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. Canaccord Genuity reiterated a “buy” rating and set a $27.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, August 7th. Robert W. Baird reiterated a “buy” rating and set a $25.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. Finally, B. Riley assumed coverage on shares of Karyopharm Therapeutics in a research report on Friday. They set a “buy” rating and a $23.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Karyopharm Therapeutics currently has an average rating of “Buy” and an average price target of $22.90.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, November 8th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.09. The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $1.21 million. Karyopharm Therapeutics had a negative net margin of 502.90% and a negative return on equity of 104.50%. As a group, sell-side analysts forecast that Karyopharm Therapeutics Inc will post -3.04 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the company. Voya Investment Management LLC grew its holdings in shares of Karyopharm Therapeutics by 24.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock valued at $317,000 after buying an additional 3,653 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in shares of Karyopharm Therapeutics by 38.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock valued at $277,000 after buying an additional 4,556 shares during the period. Bank of New York Mellon Corp boosted its stake in Karyopharm Therapeutics by 2.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 218,594 shares of the company’s stock worth $3,723,000 after purchasing an additional 4,576 shares during the period. Teachers Advisors LLC boosted its stake in Karyopharm Therapeutics by 1.4% in the 3rd quarter. Teachers Advisors LLC now owns 337,478 shares of the company’s stock worth $5,747,000 after purchasing an additional 4,800 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Karyopharm Therapeutics by 14.1% in the 3rd quarter. Wells Fargo & Company MN now owns 42,274 shares of the company’s stock worth $720,000 after purchasing an additional 5,239 shares during the period. 72.03% of the stock is owned by institutional investors.
WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2018/12/01/karyopharm-therapeutics-kpti-stock-price-down-8-6.html.
Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.